Aurinia initiates rolling submission of a new drug application to the FDA for Voclosporin in the treatment of lupus nephritis
The rolling NDA allows completed portions of an NDA to be submitted and reviewed by the Agency on an ongoing basis. Aurinia has submitted the Nonclinical Module and